Glenmede Trust CO Na Arvinas, Inc. Transaction History

Glenmede Trust CO Na

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $730,472 - $988,628	-12,120 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$65.85 - $96.21 $27,525 - $40,215	418 Added 3.57%	12,120 $995,000
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $27,596 - $40,666	-377 Reduced 3.12%	11,702 $961,000
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $730,175 - $1.02 Million	12,079 New	12,079 $930,000
Q4 2020 Feb 16, 2021	SELL	$20.19 - $84.93 $464 - $1,953	-23 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$29.88 - $56.74 $687 - $1,305	23 New	23 $0

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.